# REMINDER program: a randomized controlled trial protocol of a neuropsychological intervention for lifestyle modification in older adults at risk of dementia

**Authors:** Ana Rita Silva, Catarina Baptista, Inês Baldeiras, Maria Salomé Pinho, Margarida Lima, Rosa Marina Afonso

PMC · DOI: 10.1186/s12877-025-06714-x · BMC Geriatrics · 2025-12-10

## TL;DR

The REMINDER program is a new dementia prevention trial combining cognitive, lifestyle, and psychosocial strategies to promote brain-protective behaviors in older adults.

## Contribution

The study introduces a novel multimodal intervention targeting both cognitive and psychosocial dementia risk factors in community and clinical populations.

## Key findings

- The REMINDER program includes 20 group sessions delivered by trained neuropsychologists to promote brain-protective behaviors.
- Primary outcomes include global cognitive function and healthy lifestyle behaviors, with secondary measures covering mental health and neurodegeneration markers.

## Abstract

Most dementia risk reduction trials encompass interventions mostly focused in cognitive and health monitoring risk factors, with less focus is given to psychosocial risk factors (e.g. social isolation, depression, anxiety) which can contribute to impoverished engagement in brain protective lifestyles. The REMINDER program was designed as a multimodal intervention that integrates cognitive training, lifestyle psychoeducation, social engagement, emotion regulation, and goal setting, following the framework of internationally established dementia prevention guidelines.

This manuscript presents the protocol for two randomized controlled trials validating the REMINDER program in both community and clinical populations.

The REMINDER study includes a Community Trial (cognitively unimpaired at-risk older adults; N = 270) and a Clinical Trial (individuals with Mild Cognitive Impairment; N = 270). The Clinical Trial includes an additional arm combining caregiver education and support with the REMINDER program. Participants will attend 20 group sessions and complete pre-, post- and follow-up outcome assessments. The program is delivered by trained neuropsychologists to ensure fidelity and high-qualit implementation. Primary outcomes are global cognitive function (composite of MMSE, Word List Total Recall, Category Fluency total, and Trail Making Test Part B) and healthy lifestyle behaviors (HLAT). Secondary outcomes include additional cognitive measures (ACE-R, BRIEF-A, Digit Span), functional status (IAFAI, UPSA-Brief), psychosocial and mental health indicators (GDS-30, WHOQOL-OLD-7, LSNS-6, CORE, MCLHB-DRR), and blood-based markers of neurodegeneration (NfL, GFAP, sPDGFRβ). An exploratory outcome will monitor diagnostic transitions in the MCI subgroup (conversion to dementia) across the 18-month follow-up.

The REMINDER program contributes to dementia prevention research by combining cognitive, lifestyle, and psychosocial strategies within a group-based format, aiming to foster long-term adherence to brain-protective behaviors. Nevertheless, challenges are anticipated, including participant heterogeneity, adherence to lifestyle change, potential drop-out during follow-up, and the complexity of monitoring multiple outcomes. Addressing these limitations will be crucial to inform the future scalability and sustainability of dementia prevention interventions.

ClinicalTrial.gov Identifier NCT05296980, 22/02/2022).

## Linked entities

- **Diseases:** dementia (MONDO:0001627)

## Full-text entities

- **Genes:** GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}
- **Diseases:** anxiety (MESH:D001007), depression (MESH:D003866), dementia (MESH:D003704), Cognitive Impairment (MESH:D003072), neurodegeneration (MESH:D019636)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12801869/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12801869/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12801869/full.md

---
Source: https://tomesphere.com/paper/PMC12801869